FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2885436431> ?p ?o ?g. }

• W2885436431 abstract "Purpose: To determine the incidence of secondary malignancies in patients treated with temozolomide (TMZ) for metastatic pancreatic neuroendocrine tumors (PNET). Background: TMZ is an oral alkylating agent used to treat glioblastoma multiforme (GBM), refractory anaplastic astrocytoma (AA), and metastatic PNET. This imidazotetrazine analog of dacarbazine lacks the ability to directly crosslink DNA and is thought to be less leukemogenic than other alkylators. Given either alone, or in combination with other therapies, TMZ is associated with improved clinical outcomes. However, serious hematologic adverse events (HAEs) like agranulocytosis, lymphopenia and aplastic anemia are not uncommon. Until recently, metastatic PNET was primarily managed with somatostatin-analogs, but with more reports demonstrating therapeutic activity of TMZ-based regimens, it is anticipated that more patients with metastatic PNET will be exposed to TMZ. Methods: To determine the incidence of secondary malignancy in TMZ-treated PNET, a systematic review of all known clinical trials, case reports, and other relevant literature regarding PNET and TMZ published before September 2017 was conducted using PubMed, Embase, Cochrane Library, and the FDA database. Results: Twenty-one publications, including clinical trials, meta-analyses, case reports, and cohort studies were analyzed. HAEs ranged from agranulocytosis to myelodysplastic syndrome. No publications reported any secondary malignancies. Incidentally, at the University of Kansas Medical Center, 3 patients with TMZ-treated PNET developed hematologic malignancies. A 29-year-old female with metastatic PNET was treated with TMZ and subsequently developed acute myeloid leukemia (AML) with cytogenetics consistent with therapy-related leukemia. The second patient with TMZ-treated metastatic PNET developed diffuse large B-cell lymphoma. These two patients both had aggressive disease that was not responsive to multiple rounds of treatment. They succumbed to their hematologic malignancy, and not from metastatic PNET. The third patient is a 29-year-old who was recently diagnosed with high-grade T-cell lymphoblastic lymphoma and is currently undergoing treatment for his lymphoma. Conclusion: This review did not find any cases of secondary malignancy in TMZ-treated metastatic PNET. Yet, at our own institution we have identified 3 cases of secondary hematologic malignancies in patients treated with TMZ for PNET. We believe that the leukemogenic potential of TMZ is underreported and anticipate increased reports of secondary malignancy as the use of TMZ increases. It is important for treatment guidelines to address this risk in the decision to pursue TMZ treatment. Appropriate dosing, proper follow-up and surveillance, especially in patients who are able to live long enough to develop these hematologic cancers, is crucial. Citation Format: Nicole Balmaceda, Sunil Abhyankar, Tyler Mouw, Joaquina Baranda. Secondary malignancies in temozolomide-treated metastatic pancreatic neuroendocrine tumors [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2018; 2018 Apr 14-18; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2018;78(13 Suppl):Abstract nr 599." @default.
• W2885436431 created "2018-08-22" @default.
• W2885436431 creator A5018061611 @default.
• W2885436431 creator A5035817509 @default.
• W2885436431 creator A5057925246 @default.
• W2885436431 creator A5086587597 @default.
• W2885436431 date "2018-07-01" @default.
• W2885436431 modified "2023-09-25" @default.
• W2885436431 title "Abstract 599: Secondary malignancies in temozolomide-treated metastatic pancreatic neuroendocrine tumors" @default.
• W2885436431 doi "https://doi.org/10.1158/1538-7445.am2018-599" @default.
• W2885436431 hasPublicationYear "2018" @default.
• W2885436431 type Work @default.
• W2885436431 sameAs 2885436431 @default.
• W2885436431 citedByCount "0" @default.
• W2885436431 crossrefType "proceedings-article" @default.
• W2885436431 hasAuthorship W2885436431A5018061611 @default.
• W2885436431 hasAuthorship W2885436431A5035817509 @default.
• W2885436431 hasAuthorship W2885436431A5057925246 @default.
• W2885436431 hasAuthorship W2885436431A5086587597 @default.
• W2885436431 hasConcept C126322002 @default.
• W2885436431 hasConcept C143998085 @default.
• W2885436431 hasConcept C2776694085 @default.
• W2885436431 hasConcept C2777389519 @default.
• W2885436431 hasConcept C2778227246 @default.
• W2885436431 hasConcept C2778880634 @default.
• W2885436431 hasConcept C2779066768 @default.
• W2885436431 hasConcept C2779083369 @default.
• W2885436431 hasConcept C2780964509 @default.
• W2885436431 hasConcept C502942594 @default.
• W2885436431 hasConcept C535046627 @default.
• W2885436431 hasConcept C71924100 @default.
• W2885436431 hasConceptScore W2885436431C126322002 @default.
• W2885436431 hasConceptScore W2885436431C143998085 @default.
• W2885436431 hasConceptScore W2885436431C2776694085 @default.
• W2885436431 hasConceptScore W2885436431C2777389519 @default.
• W2885436431 hasConceptScore W2885436431C2778227246 @default.
• W2885436431 hasConceptScore W2885436431C2778880634 @default.
• W2885436431 hasConceptScore W2885436431C2779066768 @default.
• W2885436431 hasConceptScore W2885436431C2779083369 @default.
• W2885436431 hasConceptScore W2885436431C2780964509 @default.
• W2885436431 hasConceptScore W2885436431C502942594 @default.
• W2885436431 hasConceptScore W2885436431C535046627 @default.
• W2885436431 hasConceptScore W2885436431C71924100 @default.
• W2885436431 hasLocation W28854364311 @default.
• W2885436431 hasOpenAccess W2885436431 @default.
• W2885436431 hasPrimaryLocation W28854364311 @default.
• W2885436431 hasRelatedWork W1977979223 @default.
• W2885436431 hasRelatedWork W1984295121 @default.
• W2885436431 hasRelatedWork W1993694656 @default.
• W2885436431 hasRelatedWork W2057024276 @default.
• W2885436431 hasRelatedWork W2072172607 @default.
• W2885436431 hasRelatedWork W2401663852 @default.
• W2885436431 hasRelatedWork W2899756322 @default.
• W2885436431 hasRelatedWork W3011620697 @default.
• W2885436431 hasRelatedWork W3023311922 @default.
• W2885436431 hasRelatedWork W74659187 @default.
• W2885436431 isParatext "false" @default.
• W2885436431 isRetracted "false" @default.
• W2885436431 magId "2885436431" @default.
• W2885436431 workType "article" @default.